JP2022533971A5 - - Google Patents
Info
- Publication number
- JP2022533971A5 JP2022533971A5 JP2021568611A JP2021568611A JP2022533971A5 JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5 JP 2021568611 A JP2021568611 A JP 2021568611A JP 2021568611 A JP2021568611 A JP 2021568611A JP 2022533971 A5 JP2022533971 A5 JP 2022533971A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- formula
- enantiomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025062046A JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848420P | 2019-05-15 | 2019-05-15 | |
| US62/848,420 | 2019-05-15 | ||
| PCT/US2020/032941 WO2020232274A1 (en) | 2019-05-15 | 2020-05-14 | Ketamine formulation for subcutaneous injection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Division JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533971A JP2022533971A (ja) | 2022-07-27 |
| JP2022533971A5 true JP2022533971A5 (enExample) | 2023-05-23 |
Family
ID=73230954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568611A Pending JP2022533971A (ja) | 2019-05-15 | 2020-05-14 | 皮下注射のためのケタミン製剤 |
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062046A Pending JP2025114555A (ja) | 2019-05-15 | 2025-04-03 | 皮下注射のためのケタミン製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10973780B2 (enExample) |
| EP (1) | EP3968979A4 (enExample) |
| JP (2) | JP2022533971A (enExample) |
| CN (2) | CN114126596A (enExample) |
| CA (1) | CA3140046A1 (enExample) |
| WO (1) | WO2020232274A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| US11980595B2 (en) | 2018-02-15 | 2024-05-14 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| WO2019213551A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| EP3968979A4 (en) * | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
| US12233165B2 (en) | 2020-08-18 | 2025-02-25 | Oakwood Laboratories, Llc | Microsphere formulations comprising ketamine and methods for making and using the same |
| JP2023551145A (ja) | 2020-11-18 | 2023-12-07 | ベクソン バイオメディカル，インク． | 医薬化合物の錯化剤塩製剤 |
| WO2022109050A1 (en) * | 2020-11-18 | 2022-05-27 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds |
| EP4493155A1 (en) * | 2022-03-14 | 2025-01-22 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
| WO2023225113A1 (en) * | 2022-05-18 | 2023-11-23 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
| IN202221054235A (enExample) | 2022-09-22 | 2023-11-03 | ||
| WO2024171074A1 (en) * | 2023-02-15 | 2024-08-22 | Clearmind Medicine Inc. | Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof |
| US12005035B1 (en) * | 2023-08-14 | 2024-06-11 | Daniel C. Javitt | Compositions and methods for treatment of chronic pain and depression |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5352683A (en) * | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| CA2230690C (en) * | 1995-08-30 | 2008-12-23 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| ATE367828T1 (de) * | 1998-04-03 | 2007-08-15 | Novartis Vaccines & Diagnostic | Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel |
| CN1172908C (zh) | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| AR046769A1 (es) * | 2003-12-22 | 2005-12-21 | Schering Corp | Composiciones farmaceuticas |
| CN1939298A (zh) | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| BRPI0809843A2 (pt) * | 2007-04-26 | 2014-09-23 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| WO2013056229A1 (en) * | 2011-10-14 | 2013-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| US20130296437A1 (en) | 2012-05-04 | 2013-11-07 | E-Therapeutics Plc | Treatment of Depression |
| US10124940B2 (en) | 2012-09-11 | 2018-11-13 | Zolo Solutions, Inc. | Systems, methods, and devices for dispensing one or more substances |
| EP3442940A1 (en) * | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| EP3968979A4 (en) * | 2019-05-15 | 2023-03-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
-
2020
- 2020-05-14 EP EP20804815.7A patent/EP3968979A4/en active Pending
- 2020-05-14 CN CN202080051484.6A patent/CN114126596A/zh active Pending
- 2020-05-14 CN CN202511966779.7A patent/CN121489917A/zh active Pending
- 2020-05-14 US US16/874,485 patent/US10973780B2/en active Active
- 2020-05-14 JP JP2021568611A patent/JP2022533971A/ja active Pending
- 2020-05-14 CA CA3140046A patent/CA3140046A1/en active Pending
- 2020-05-14 WO PCT/US2020/032941 patent/WO2020232274A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/187,641 patent/US20210186896A1/en active Pending
-
2025
- 2025-04-03 JP JP2025062046A patent/JP2025114555A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533971A5 (enExample) | ||
| JP2025114555A5 (enExample) | ||
| KR810000900B1 (ko) | 항생물질 조성제의 안정화 방법 | |
| US20040209843A1 (en) | Aqueous cilostazol preparation for injection | |
| JP3933683B2 (ja) | アジスロマイシン含有水性医薬組成物及びその調製方法 | |
| CN108697726B (zh) | 液态药物制剂 | |
| TWI538673B (zh) | 包含撲熱息痛的醫藥組成物及其製備方法 | |
| JP7110196B2 (ja) | カルバメート化合物を含む非経口用液剤 | |
| EP2934593B1 (en) | Cabazitaxel composition | |
| TW200808690A (en) | Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]-phenethyl}amino)methyl]benzoic acid | |
| CN114746092A (zh) | D-苯丙胺化合物、组合物、以及制备和使用它们的方法 | |
| KR20100051694A (ko) | 주사제, 주사 용액, 및 주사 키트 제제 | |
| CN1812794B (zh) | 溶液药用组合物 | |
| BG62197B1 (bg) | Антимигренно средство за интраназално приложение | |
| JP7090845B2 (ja) | パロノセトロン含有液体組成物 | |
| JP7267640B2 (ja) | 希釈安定性に優れたテニポシド注射用溶液及びその調製方法 | |
| CA3046458C (en) | Parenteral liquid preparation comprising carbamate compound | |
| EP1682149B1 (en) | Injectable gabapentin compositions | |
| KR20250020129A (ko) | 고농도의 아포모르핀을 포함하는 수성 배합물 및 그의 용도 | |
| US20040019013A1 (en) | Formulation for the parenteral application of a sodium channel blocker | |
| HK40078104A (en) | D-amphetamine compounds, compositions, and processes for making and using the same | |
| HK40063844B (zh) | 一种药物组合物及其应用 | |
| JP2000119177A (ja) | 鎮痛剤 | |
| HK40015062A (en) | Parenteral liquid preparation comprising carbamate compound | |
| WO2018109731A1 (en) | Pharmaceutical compositions of taxane and its derivatives |